The stable detection ability of ctDNA makes it of great value in guiding the emerging targeted therapy and immunotherapy for metastatic bladder cancer, especially in terms of targeted changes in the MAPK/ERK and PI3K/AKT/mTOR pathways (Vandekerkhove et al., 2017). This evidence concerns the gene MTOR and urinary bladder cancer.